Kensey Nash’s Orthopedics Business Fortified By New Customers
This article was originally published in The Gray Sheet
Executive Summary
Kensey Nash inked major supply agreements in the second quarter, expanding the firm's customer base and accelerating the rebound of its biomaterials business
You may also be interested in...
Kensey Nash Looks To Augment TriActiv Embolic Protection Offerings
Kensey Nash is counting on the next-generation TriActiv Fx and TriActiv ProGuard embolic protection systems to substantially strengthen its endovascular business
Kensey Nash Predicts Orthopedic Growth In 2006 After Orthovita Disappoints
Kensey Nash expects that updating the Vitoss Foam bone-void filler line will revive sluggish sales to biomaterials company Orthovita in 2006
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”